Do you want to read an article? Please log in or register.
Adjuvant Targeted Therapy in BRAF-Mutated Melanoma
Further Publications
SPECIAL REPORT
Related content
RECOMMENDED
Skin Cancer
Targeted Therapy in Advanced Melanoma With Rare <i>BRAF</i> Mutations
J Clin Oncol.
Menzer C, Menzies AM, Carlino MS, Reijers I, Groen EJ, Eigentler T, de Groot JWB, van der Veldt AAM, Johnson DB, Meiss F, Schlaak M, Schilling B, Westgeest HM, Gutzmer R, Pföhler C, Meier F, Zimmer L, Suijkerbuijk KPM, Haalck T, Thoms KM, Herbschleb K, Leichsenring J, Menzer A, Kopp-Schneider A, Long GV, Kefford R, Enk A, Blank CU, Hassel JC
doi: 10.1200/JCO.19.00489.
Skin Cancer
Systemic Therapy for Previously Untreated Advanced BRAF-Mutated Melanoma: A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials
JAMA Oncol.
Devji T, Levine O, Neupane B, Beyene J, Xie F
doi: 10.1001/jamaoncol.2016.4877.
Skin Cancer
Illustrative cases for monitoring by quantitative analysis of BRAF/NRAS ctDNA mutations in liquid biopsies of metastatic melanoma patients who gained clinical benefits from anti-PD1 antibody therapy
Melanoma Res.
Seremet T, Planken S, Schreuer M, Jansen Y, Delaunoy M, El Housni H, Lienard D, Del Marmol V, Heimann P, Neyns B
doi: 10.1097/
Skin Cancer
Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy
Ann Oncol.
Owen CN, Shoushtari AN, Chauhan D, Palmieri DJ, Lee B, Rohaan MW, Mangana J, Atkinson V, Zaman F, Young A, Hoeller C, Hersey P, Dummer R, Khattak MA, Millward M, Patel SP, Haydon A, Johnson DB, Lo S, Blank CU, Sandhu S, Carlino MS, Larkin JMG, Menzies AM, Long GV
doi: 10.1016/j.annonc.2020.04.471.
RECOMMENDED
Breast Cancer
Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Guideline Update
★ 3
Recommended by
Alexander Meisel, Faculty Member
J Clin Oncol.
Denduluri N, Somerfield MR, Chavez-MacGregor M, Comander AH, Dayao Z, Eisen A, Freedman RA, Gopalakrishnan R, Graff SL, Hassett MJ, King TA, Lyman GH, Maupin GR, Nunes R, Perkins CL, Telli ML, Trudeau ME, Wolff AC, Giordano SH
doi: 10.1200/JCO.20.02510.Visit the original publication at ncbi.nlm.nih.gov
Lung, Respiratory and Thoracic Cancer
Molecular landscape of BRAF-mutant NSCLC reveals an association between clonality and driver mutations and identifies targetable non-V600 driver mutations
J Thorac Oncol.
Negrao MV, Raymond VM, Lanman RB, Robichaux JP, He J, Nilsson MB, Ng PKS, Amador BE, Roarty EB, Nagy RJ, Banks KC, Zhu VW, Ng C, Chae YK, Clarke JM, Crawford JA, Meric-Bernstam F, Ou SH, Gandara DR, Heymach JV, Bivona TG, McCoach CE
doi: 10.1016/j.jtho.2020.05.021.
Skin Cancer
Multicenter, real-life experience with checkpoint inhibitors and targeted therapy agents in advanced melanoma patients in Switzerland
Melanoma Res.
Mangana J, Cheng PF, Kaufmann C, Amann VC, Frauchiger AL, Stögner V, Held U, von Moos R, Michielin O, Braun RP, Levesque MP, Goldinger SM, Dummer R
doi: 10.1097/
Skin Cancer
Dabrafenib plus trametinib is effective in the treatment of BRAF V600-mutated metastatic melanoma patients: analysis of patients from the dabrafenib plus trametinib Named Patient Program (DESCRIBE II)
Melanoma Res.
Atkinson V, Sandhu S, Hospers G, Long GV, Aglietta M, Ferrucci PF, Tulyte S, Cappellini GCA, Soriano V, Ali S, Poprach A, Cesas A, Rodriguez-Abreu D, Lau M, de Jong E, Legenne P, Stein D, King B, van Thienen JV
doi: 10.1097/CMR.0000000000000654.
ERBB2-Mutated Metastatic Non-Small Cell Lung Cancer: Response and Resistance to Targeted Therapies
J Thorac Oncol.
Chuang JC, Stehr H, Liang Y, Das M, Huang J, Diehn M, Wakelee HA, Neal JW
doi: 10.1016/j.jtho.2017.01.023.